CXC chemokine ligand 4 (CXCl4) is a platelet-derived mediator of experimental liver fibrosis

Hepatology

Volumn 51, Issue 4, 2010, Pages 1345-1353

  Zaldivar, Mirko Moreno ^a   Pauels, Katrin ^a   Von Hundelshausen, Philipp ^a,c   Berres, Marie Luise ^a   Schmitz, Petra ^a   Bornemann, J̈org ^d   Kowalska, M Anna ^f   Gassler, Nikolaus ^e   Streetz, Konrad L ^a   Weiskirchen, Ralf ^a   Trautwein, Christian ^a   Weber, Christian ^b   Wasmuth, Hermann E ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b Institute for Molecular Cardiovascular Research   (Germany)

^c Department of Medicine i ^*  (Germany)

^d Electron Microscopy Facility   (Germany)

^e Institute of Pathology   (Germany)

^f CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CHEMOKINE; CARBON TETRACHLORIDE; COLLAGEN FIBRIL; CXC CHEMOKINE LIGAND 4; GELATINASE B; INTERLEUKIN 10; MESSENGER RNA; THIOACETAMIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELL STIMULATION; CHEMOTAXIS; CHRONIC LIVER DISEASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ELECTRON MICROSCOPY; FLUORESCENCE ACTIVATED CELL SORTING; GENE DELETION; HEPATITIS C; HEPATITIS C VIRUS; HISTOLOGY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER FIBROSIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MOUSE; NEUTROPHIL CHEMOTAXIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; STELLATE CELL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; WILD TYPE;

ANIMALS; BLOOD PLATELETS; CARBON TETRACHLORIDE; CHEMOKINES, CXC; CHEMOTAXIS; HEPATIC STELLATE CELLS; HEPATITIS C; HUMANS; LIVER CIRRHOSIS, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEUTROPHIL INFILTRATION; PLATELET ACTIVATION; RNA, MESSENGER;

EID: 77950620236     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23435     Document Type: Article

References (41)

1. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006;130:231-264; quiz, 214-237.
2. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008;134:1655-1669.
3. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008; 214:199-210.
4. Holt AP, Salmon M, Buckley CD, Adams DH. Immune interactions in hepatic fibrosis. Clin Liver Dis 2008;12:861-882.
5. CalvarusoV, Maimone S,Gatt A, Tuddenham E, Thursz M,Pinzani M, et al. Coagulation and fibrosis in chronic liver disease. Gut 2008;57:1722-1727.
6. Wright M, Goldin R, Hellier S, Knapp S, Frodsham A, Hennig B, et al. Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection. Gut 2003;52:1206-1210.
7. Papatheodoridis GV, Papakonstantinou E, Andrioti E, Cholongitas E, Petraki K, Kontopoulou I, et al. Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis. Gut 2003;52:404-409.
8. Anstee QM, Goldin RD, Wright M, Martinelli A, Cox R, Thursz MR. Coagulation status modulates murine hepatic fibrogenesis: implications for the development of novel therapies. J Thromb Haemost 2008;6:1336-1343.
9. Iannacone M, Sitia G, Isogawa M, Marchese P, Castro MG, Lowenstein PR, et al. Platelets mediate cytotoxic T lymphocyte-induced liver damage. Nat Med 2005;11:1167-1169.
10. Lang PA, Contaldo C, Georgiev P, El-Badry AM, Recher M, Kurrer M, et al. Aggravation of viral hepatitis by platelet-derived serotonin. Nat Med 2008;14:756-761.
11. Lesurtel M,Graf R, Aleil B, Walther DJ, Tian Y, Jochum W, et al. Platelet-derived serotonin mediates liver regeneration. Science 2006;312:104-107.
12. Fujita K, Nozaki Y, Wada K, Yoneda M, Endo H, Takahashi H, et al. Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease. Gut 2008;57:1583-1591.
13. Nocito A, Georgiev P, Dahm F, Jochum W, Bader M, Graf R, et al. Platelets and platelet-derived serotonin promote tissue repair after normo-thermic hepatic ischemia in mice. HEPATOLOGY 2007;45:369-376.
14. von Hundelshausen P, Petersen F, Brandt E. Platelet-derived chemokines in vascular biology. Thromb Haemost 2007;97:704-713.
15. Gleissner CA, von Hundelshausen P, Ley K. Platelet chemokines in vascular disease. Arterioscler Thromb Vasc Biol 2008;28:1920-1927.
16. Rollins BJ. Chemokines. Blood 1997;90:909-928.
17. Lasagni L, Francalanci M, Annunziato F, Lazzeri E, Giannini S, Cosmi L, et al. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med 2003;197:1537-1549.
18. Pitsilos S, Hunt J, Mohler ER, Prabhakar AM, Poncz M, Dawicki J, et al. Platelet factor 4 localization in carotid atherosclerotic plaques: correlation with clinical parameters. Thromb Haemost 2003;90:1112-1120.
19. Sachais BS, Turrentine T, Dawicki McKenna JM, Rux AH, Rader D, Kowalska MA. Elimination ofplatelet factor4 (PF4) from platelets reduces atherosclerosis in C57Bl/6 and apoE-/-mice. Thromb Haemost 2007;98: 1108-1113.
20. Dominguez M, Miquel R, Colmenero J, Moreno M, Garć?a-Pagán JC, Bosch J, et al. Hepatic expression of CXC chemokines predicts portal hypertension and survival in patients with alcoholic hepatitis. Gastroen-terology 2009;136:1639-1650.
21. PanasiukA,Prokopowicz D, ZakJ, Matowicka-Karna J,Osada J,Wysocka J. Activation of blood platelets in chronic hepatitis and liver cirrhosis P-selectin expression on blood platelets and secretory activity of beta-thromboglobulin and platelet factor-4. Hepatogastroenterology 2001;48: 818-822.
22. Wasmuth HE, Lammert F, Zaldivar MM, Weiskirchen R, Hellerbrand C, Scholten D, et al. Anti-fibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology 2009;137:309-319.
23. Wasmuth HE, Tag CG, Van deLeur E, HellerbrandC,MuellerT,Berg T, et al. The Marburg I variant (G534E) of the factor VII-activating protease FSAP determines liver fibrosis in hepatitis C infection by reduced proteol-ysis of PDGF-BB. HEPATOLOGY 2009;49:775-780.
24. Kato M, Iwamoto H, Higashi N, Sugimoto R, Uchimura K, Tada S, et al. Role of Rho small GTP binding protein in the regulation of actin cytoskel-eton in hepatic stellate cells. J Hepatol 1999;31:91-99.
25. Borkham-Kamphorst E, van Roeyen CR, Ostendorf T, Floege J, Gressner AM, Weiskirchen R. Pro-fibrogenic potential of PDGF-D in liver fibrosis. J Hepatol 2007;46:1064-1074.
26. Iredale JP. Models ofliver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 2007;117:539-548.
27. Srivastava K, Cockburn IA, Swaim A, Thompson LE, Tripathi A, Fletcher CA, et al. Platelet factor 4 mediates inflammation in experimental cerebral malaria. Cell Host Microbe 2008;4:179-187.
28. von Hundelshausen P, Koenen RR, Sack M, Mause SF, Adriaens W, Proudfoot AE, et al. Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. Blood 2005;105: 924-930.
29. Holt AP, Haughton EL, Lalor PF, Filer A, Buckley CD, Adams DH. Liver myofibroblasts regulate infiltration and positioning of lymphocytes in human liver. Gastroenterology 2009;136:705-714.
30. Henderson NC, Iredale JP. Liver fibrosis: cellular mechanisms of progression and resolution. Clin Sci (Lond) 2007;112:265-280.
31. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006;354:610-621.
32. Karlmark KR, Wasmuth HE, Trautwein C, Tacke F. Chemokine-directed immune cell infiltration in acute and chronic liver disease. Expert Rev Gastroenterol Hepatol 2008;2:233-242.
33. Marra F. Chemokines in liver inflammation and fibrosis. Front Biosci 2002;7:d1899-d1914.
34. Panasiuk A, Zak J, Kasprzycka E, Janicka K, Prokopowicz D. Blood platelet and monocyte activations and relation to stages of liver cirrhosis. World J Gastroenterol 2005;11:2754-2758.
35. Maher JJ. Interactions between hepatic stellate cells and the immune system. Semin Liver Dis 2001;21:417-426.
36. Oakley F, Mann J, Nailard S, Smart DE, Mungalsingh N, Constandinou C, et al. Nuclear factor-kappaB1 (p50) limits the inflammatory and fibro-genic responses to chronic injury. Am J Pathol 2005;166:695-708.
37. Chosay JG, Essani NA, Dunn CJ, Jaeschke H. Neutrophil margination and extravasation in sinusoids and venules of liver during endotoxin-in-duced injury. Am J Physiol 1997;272:G1195-G1200.
38. Safadi R, Ohta M, Alvarez CE, Fiel MI, Bansal M, Mehal WZ, et al. Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. Gastroenterology 2004; 127:870-882.
39. Seki E, De Minicis S, Gwak GY, Kluwe J, Inokuchi S, Bursill CA, et al. CCR1 and CCR5 promote hepatic fibrosis in mice. J Clin Invest 2009; 119:1858-1870.
40. Bonacchi A, Petrai I, Defranco RM, Lazzeri E, Annunziato F, Efsen E, et al. The chemokine CCL21 modulates lymphocyte recruitment and fibrosis in chronic hepatitis C. Gastroenterology 2003;125:1060-1076.
41. Koenen RR, von Hundelshausen P, Nesmelova IV, Zernecke A, Liehn EA, Sarabi A, et al. Disrupting functional interactions between platelet chemo-kines inhibits atherosclerosis in hyperlipidemic mice. Nat Med 2009;15: 97-103.